Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORI-C101
- Development stage
- Phase 2
- Lead developer
- OriCell Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
ORI-C101 is an autologous chimeric antigen receptor T (CAR-T) cell therapy developed by OriCell Therapeutics for the treatment of advanced liver cancer. It specifically targets glypican-3 (GPC3), a protein commonly overexpressed in certain liver cancers. The therapy involves engineering a patient's own T cells to express a CAR that recognizes GPC3, enabling targeted immunologic cytotoxicity against tumor cells. In clinical studies, ORI-C101 has demonstrated promising safety and efficacy profiles in patients with GPC3-positive advanced liver cancer, including an objective response rate of 44% and disease control rate of 78%. The product is currently being evaluated in phase I/II trials in China[1][3][7].
- Other names
- Ori-C101Ori-C-101Ori-C 101Ori CAR 001autologous anti-GPC3 CAR-T lymphocytes
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on ORI-C101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORI-C101.